Comparing Antipsychotic Medications in LBD Over Time
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorThe University of Texas Health Science Center at San Antonio
About this trial
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Eligibility criteria
Qualifiers
Patients seen in the neurology clinic at UT Health San Antonio
Diagnosed with psychosis due to PD or DLB
Requiring initiation of an antipsychotic medication
Clinical equipoise between quetiapine and pimavanserin must exist
Disqualifiers
Medical contraindication to either medication
Caregiver unavailable to complete NPI-Q
Currently taking an antipsychotic medication
Prescribing provider unwilling to manage either medication
Trial design
Treatments tested in this trial
- Pimavanserin
- Quetiapine
Treatment groups
94 Participants
are divided into 2 treatment groupsSponsors and collaborators
The University of Texas Health Science Center at San Antonio
Lead sponsor
Alzheimer's Association
Collaborator
Source ClinicalTrials.gov